Merrimack Pharmaceuticals Inc (NASDAQ:MACK)
During the Trading Day
| 6.23 |  +0.315 / +5.33% |
Data as of 3:59pm ET | Day’s Change |
During After-Hours Switch to standard view »
| 6.23 |  0.00 / 0.00% |
Volume: 14.3K |
Latest MACK News | Press Releases
No recent news for Merrimack Pharmaceuticals Inc.
Today’s Trading
| Previous close | 5.92 |
| Today’s open | 6.00 |
| Day’s range | 5.99 - 6.23 |
| Volume | 1,304,538 |
| Average volume (3 months) | 2,349,534 |
| Market cap | $611.6M |
| Dividend yield | -- |
Data as of 3:59pm ET, 07/30/2014
Growth & Valuation
| Earnings growth (last year) | -5.32% |
| Earnings growth (this year) | +12.25% |
| Earnings growth (next 5 years) | +5.61% |
| Revenue growth (last year) | -2.32% |
| P/E ratio | NM |
| Price/Sales | 11.04 |
| Price/Book | -- |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| HZNPHorizon Pharma Inc | +0.64 | +7.80% |
| NLNKNewLink Genetics Cor... | +1.06 | +4.87% |
| OREXOrexigen Therapeutic... | -0.11 | -2.12% |
| MGNXMacroGenics Inc | -0.03 | -0.14% |
Data as of 3:59pm ET, 07/30/2014
Financials
| Next reporting date | August 8, 2014 |
| EPS forecast (this quarter) | -$0.30 |
| Annual revenue (last year) | $47.8M |
| Annual profit (last year) | -$130.9M |
| Net profit margin | -273.98% |
Profile
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Robert J. Mulroy |
Senior Vice President- Operations William M. McClements |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
